Omnicell Acquires ReCept Holdings
December 29, 2021
Omnicell entered into a definitive agreement to acquire ReCept Holdings, a specialty pharmacy management services provider for health systems, clinics, and physician groups, for $100 million in total aggregate cash consideration (subject to customary adjustments). Omnicell said the acquisition expands its Advanced Services portfolio and supports its “Autonomous Pharmacy” vision by improving access to and coordination of complex specialty medications.
- Buyers
- Omnicell, Inc.
- Targets
- ReCept Holdings, Inc.
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Omnicell Acquires MarkeTouch Media
December 31, 2021
Healthcare Services
Omnicell, Inc. acquired pharmacy software and patient engagement provider MarkeTouch Media, LLC for $82 million in cash. The deal expands Omnicell’s EnlivenHealth footprint in the retail and specialty pharmacy markets and adds MarkeTouch’s mobile/web-based SaaS patient engagement capabilities to accelerate Omnicell’s SaaS roadmap.
-
Gifthealth Acquires Occam Health Services
September 2, 2025
Healthcare Services
Gifthealth has acquired Occam Health Services to combine Gifthealth's digital-first pharmacy automation and dispensing network with Occam's high-touch specialty hub and patient support capabilities. The acquisition creates an integrated digital pharmacy platform and patient access hub aimed at improving patient access, refill success, and delivery speed for biopharma brands.
-
Recro Pharma Acquires IRISYS (San Diego)
August 13, 2021
Pharmaceuticals
Recro Pharma (NASDAQ: REPH) acquired San Diego–based CDMO IRISYS for approximately $49.85 million in cash, stock and a seller promissory note, transforming Recro into a bi‑coastal, full‑service CDMO. The acquisition expands Recro's capabilities (including aseptic fill/finish and lyophilization), diversifies its client base and adds near‑term revenue and backlog.
-
Biogen Acquires Reata Pharmaceuticals
July 28, 2023
Biotechnology
Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.
-
Recipharm AB Acquires Vibalogics from Ampersand Capital Partners
February 18, 2022
Biotechnology
Recipharm AB, a global CDMO based in Sweden, has agreed to acquire Vibalogics, a virotherapy-focused CDMO and Ampersand Capital Partners portfolio company. The deal expands Recipharm's capabilities into viral vaccines, viral vectors and oncolytic virus manufacturing while Vibalogics will continue operating from its Boxborough, MA and Cuxhaven, Germany facilities.
-
Revelation Pharma (Osceola Capital) Acquires Five Compounding Pharmacies
January 27, 2022
Healthcare Services
Revelation Pharma, a PE-backed specialty pharmacy platform sponsored by Osceola Capital, completed add-on acquisitions of five compounding pharmacies: Innovation Compounding, Pencol Compounding Pharmacy, Pharmacy Specialists Compounding, Wise Pharmacy, and Convex Pharmacy. The deals expand Revelation's geographic footprint and clinical capabilities across key U.S. regions and will see some locations merged into existing Revelation businesses (e.g., Wise into Pencol; Convex into Everwell).
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.